Preview

Медицинский Совет

Расширенный поиск

КОМБИНИРОВАННЫЕ РЕЖИМЫ ХИМИОТЕРАПИИ ПРИ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.21518/2079-701X-2017-6-62-70

Полный текст:

Аннотация

Рак поджелудочной железы характеризуется агрессивным течением и высоким метастатическим потенциалом, в связи с чем в большинстве случаев заболевание выявляется на неоперабельных стадиях. Основным методом лечения местнораспространенного и метастатического рака поджелудочной железы является химиотерапия. До недавнего времени стандартом химиотерапии данной патологии считалась монотерапия гемцитабином, пока в клиническую практику не вошли более эффективные режимы комбинированной химиотерапии (FOLFIRINOX и комбинация nab-паклитаксела с гемцитабином). Назначение данных схем химиотерапии лимитирует относительно высокая токсичность, что делает невозможным их применение у ослабленных пациентов и у больных с серьезной сопутствующей патологией. В настоящей работе рассматриваются критерии выбора оптимального режима комбинированной химиотерапии на основе оценки состояния пациента, возможности управления побочными эффектами химиотерапии, а также молекулярно-биологические характеристики опухоли.

Об авторах

А. С. ПОПОВА
Российский онкологический научный центр им. Н.Н. Блохина Минздрава России
Россия


И. А. ПОКАТАЕВ
Российский онкологический научный центр им. Н.Н. Блохина Минздрава России
Россия
к.м.н.


С. А. ТЮЛЯНДИН
Российский онкологический научный центр им. Н.Н. Блохина Минздрава России
Россия
д.м.н., профессор


Список литературы

1. Состояние онкологической помощи населению России в 2014 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2015. 236 с.

2. SEER Stat Fact Sheets: Pancreas Cancer, 2015 // URL: http://seer.cancer.gov/statfacts/html/pancreas.html

3. Kourie HR et al. Is metastatic pancreatic cancer an untargetable malignancy? World journal of gastrointestinal oncology, 2016, 8(3): 297-304.

4. Glimelius B et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology, 1996, 7(6): 593-600.

5. Raderer M et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and l-leucovorin: A phase II study. Annals of oncology, 1997, 8(8): 797-799.

6. Bruckner HW et al. Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine. Oncology, 1983, 40(3): 165-169.

7. Burris 3rd HA et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 1997, 15(6): 2403-2413.

8. Berlin JD et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology, 2002, 20(15): 3270-3275.

9. Rocha Lima CM et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology, 2004, 22(18): 3776-3783.

10. Louvet C et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology, 2005, 23(15): 3509-3516.

11. Oettle H et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in pati ents with unresectable or metastatic pancreatic cancer. Annals of Oncology, 2005, 16(10): 1639-1645.

12. Abou-Alfa GK et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology, 2006, 24(27): 4441-4447.

13. Heinemann V et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology, 2006, 24(24):3946-3952.

14. Herrmann R et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology, 2007, 25(16): 2212-2217.

15. Cunningham D et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology, 2009 27 (33): 5513-5518.

16. Colucci G et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single- agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. Journal of Clinical Oncology, 2010, 28(10): 1645-1651.

17. Ueno H et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. Journal of Clinical Oncology, 2013, 31(13): 1640-1648.

18. Bramhall SR et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. British journal of cancer, 2002, 87(2): 161-167.

19. Van Cutsem E et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology, 2004, 22(8): 1430-1438.

20. Philip PA et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial S0205. Journal of Clinical Oncology, 2010, 28 (22): 3605-3610.

21. Infante JR et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European journal of cancer, 2014, 50(12): 2072-2081.

22. Van Cutsem E et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2009, 27(13): 2231-2237.

23. Kindler H. L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology, 2010, 28(22): 3617-3622.

24. Kindler HL et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double- blind randomised phase 3 study. The Lancet Oncology, 2011, 12(3): 256-262.

25. Gonçalves A et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of oncology, 2012, 23(11): 2799-2805.

26. Rougier P et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European journal of cancer, 2013, 49(12): 2633-2642.

27. Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 2011, 364(19): 1817-1825.

28. Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 2013, 369(18): 1691-1703.

29. Alexis F et al. Nanoparticle technologies for cancer therapy. Drug delivery Springer Berlin Heidelberg, 2010, 197: 55-86.

30. Lammers T et al. Tumour-targeted nanomedicines: principles and practice. British journal of cancer, 2008, 99(3): 392-397.

31. Rajeshkumar NV et al. Superior therapeutic efficacy of nab-paclitaxel over cremophorbased paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British journal of cancer, 2016, 115: 442-453.

32. Alvarez R et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. British journal of cancer, 2013, 109(4): 926-933.

33. Von Hoff DD et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advan ced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology, 2011, 29(34): 4548-4554.

34. Frese KK et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer discovery, 2012, 2(3): 260-269.

35. Neesse A et al. SPARC independent drug delivery and antitumour effects of nab- paclitaxel in genetically engineered mice. Gut, 2014, 63(6): 974-983.

36. Goldstein D et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: longterm survival from a phase III trial. Journal of the National Cancer Institute, 2015, 107(2): 413-419.

37. Philip PA et al. LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC). Journal of Clinical Oncology, 2016, 34: 4_suppl, TPS477-TPS477.

38. Moore MJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2007, 25(15): 1960-1966.

39. Van Cutsem E et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British journal of cancer, 2014, 111(11): 2067-2075.

40. Hammel P et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA, 2016, 315(17): 1844-1853.

41. Tan DSP et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology, 2008, 26(34): 5530-5536.

42. Cass I et al. Improved survival in women with BRCA‐associated ovarian carcinoma. Cancer, 2003, 97(9): 2187-2195.

43. Yang D et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 2011, 306(14): 1557-1565.

44. Silver DP et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of Clinical Oncology, 2010, 28(7): 1145-1153.

45. Yun J et al. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene, 2005, 24(25): 4009-4016.

46. Ledermann JA et al. Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Journal of Clinical Oncology, 2016, 34(suppl; abstr 5501).

47. Poplin E et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2009, 27(23): 3778-3785.

48. Golan T et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. British journal of cancer, 2014, 111(6): 1132-1138.

49. Fogelman D et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer chemotherapy and pharmacology, 2015, 76(3): 489-498.

50. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer (Version 2.2017). https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Accessed December 7, 2016.

51. Waddell N et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518(7540): 495-501.

52. Mackey JR et al. Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates, 1998, 1(5): 310-324.

53. Mackey JR et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer research, 1998, 58(19): 4349-4357.

54. Farrell JJ et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology, 2009, 136(1): 187-195.

55. Greenhalf W et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Journal of the National Cancer Institute, 2014, 106(1): djt347.

56. Ormanns S et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO- PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer, 2014, 50(11): 1891-1899.

57. Poplin E et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Journal of Clinical Oncology, 2013, 31(35): 4453-4461.

58. Sinn M et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine–Results from the CONKO-001 trial. European Journal of Cancer, 2015, 51(12): 1546-1554.

59. Svrcek M et al. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Histopathology, 2015, 66(3): 457-462.

60. Capello M et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. Journal of the National Cancer Institute, 2015, 107(8): 132.

61. da Cunha Santos G et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116(24): 5599-5607.

62. Giordano G et al. Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab- P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts). European Journal of Cancer, 2015, 51: S445.

63. National Comprehensive Cancer Network. Myeloid Growth Factors (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf Accessed April 28, 2017.

64. Hosein PJ et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline- resectable locally advanced pancreatic adenocarcinoma. BMC cancer, 2012, 12(1): 199.

65. Stein SM et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British journal of cancer, 2016, 114(7): 809-812.

66. Innocenti F et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. Journal of Clinical Oncology, 2014, 32(22): 2328-2334.

67. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27: 1386-1422.

68. ABRAXANE – prescribing information / Abraxis BioScience, LLC. URL: http://www.abraxane.com/wp-content/pi/prescribing-info.html.

69. Снеговой А.В. и др. RUSSCO. Практические рекомендации по лечению анемии у онкологических больных (Версия 2016). URL: http://www.rosoncoweb.ru/standarts/RUSSCO/2016/32.pdf.

70. Bennett CL et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA, 2008, 299(8): 914-924.

71. Bohlius J et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet, 2009, 373(9674): 1532-1542.

72. Tonelli M et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Canadian Medical Association Journal, 2009, 180(11): E62-E71.

73. Smith EM et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 2013, 309(13): 1359-1367.

74. Suzuki H et al. The effect of duloxetine on chemotherapy-induced peripheral neuropathy in advanced pancreatic cancer patients receiving gemcitabine plus nab- paclitaxel treatment. Journal of Clinical Oncology, 2017, 35(suppl. 4): 453-453.

75. Покатаев И.А. и др. RUSSCO. Практические рекомендации по лекарственному лечению рака поджелудочной железы (Версия 2016). URL: http://www.rosoncoweb.ru/standarts/RUSSCO/2016/25.pdf.

76. Ducreux M et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26(suppl. 5): 56-68.

77. Davendra PS et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34(23): 2784-2796.

78. Kim GP et al. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert Review of Clinical Pharmacology, 2017, 10(5): 559-565.


Для цитирования:


ПОПОВА А.С., ПОКАТАЕВ И.А., ТЮЛЯНДИН С.А. КОМБИНИРОВАННЫЕ РЕЖИМЫ ХИМИОТЕРАПИИ ПРИ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ. Медицинский Совет. 2017;(6):62-70. https://doi.org/10.21518/2079-701X-2017-6-62-70

For citation:


POPOVA A.S., POKATAEV I.A., TYULYANDIN, S.A. COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER. Medical Council. 2017;(6):62-70. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-62-70

Просмотров: 276


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)